MERCK WANTS PIECE OF ANTIDEPRESSANT BOOM: UNVEILS SUBSTANCE P ANTAGONIST "MEDICAL BREAKTHROUGH" TO ANALYSTS; VIOXX COX-2 INHIBITOR NDA SLATED FOR '98

Merck's "breakthrough" substance P antagonist MK-869 has just entered Phase IIb in depression, Merck Exec VP-Science & Technology Edward Scolnick told analysts Dec. 3 at the company's Whitehouse Station, N.J. headquarters.